Comparison · NCT02338843-sae
LJPC-501 (Angiotensin II) vs Placebo (0.9% Sodium Chloride Solution): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LJPC-501 (Angiotensin II) vs Placebo (0.9% Sodium Chloride Solution): serious adverse events. Trial comparisons, record NCT02338843-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02338843-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.607 | 0.531 | 0.679 | wilson | |
| Risk in group 2 | 0.671 | 0.594 | 0.739 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0635 | -0.166 | 0.0413 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.905 | 0.768 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.759 | 0.48 | 1.2 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on LJPC-501 (Angiotensin II) than on Placebo (0.9% Sodium Chloride Solution) | 15.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LJPC-501 (Angiotensin II) | Treatment arm~LJPC-501: Treatment arm | 99 | 163 | EG000 |
| Group 2 | Placebo (0.9% Sodium Chloride Solution) | Placebo arm~Placebo: PBO | 106 | 158 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected from study drug initiation through Day 28.
Source ClinicalTrials.gov
Trial
- Title
- A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
- NCT number
- NCT02338843
- Phases
- PHASE3
- Conditions
- Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
- Interventions
- LJPC-501, Placebo
- Lead sponsor
- La Jolla Pharmaceutical Company
- Results first posted
- 2018-01-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02338843?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02338843-sae